Immunotherapy for drug abuse

CNS and Neurological Disorders - Drug Targets

Volumn 10, Issue 8, 2011, Pages 876-879

  Shen, Xiaoyun ^a   Kosten, Thomas R ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cocaine; Immunotherapies; Substance use disorders; TA CD; Vaccine

Indexed keywords

ANTIBODY; COCAINE; COCAINE VACCINE; UNCLASSIFIED DRUG; VACCINE;

COCAINE DEPENDENCE; DRUG ABUSE; DRUG MEGADOSE; DRUG SAFETY; HUMAN; HYPERTENSION; IMMUNOTHERAPY; INJECTION SITE PAIN; LOW DRUG DOSE; NONHUMAN; REVIEW; SIDE EFFECT; TACHYCARDIA; TEMPERATURE; TREATMENT RESPONSE;

EID: 84857696112     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/187152711799219352     Document Type: Review

References (28)

1. World drug report 2011. http://www.scribd.com/doc/49212453/World-Drug-Report-2010-Lo-res
2. Kreek, M.J.; Borg, L.; Ducat, E.; Ray, B. Pharmacotherapy in the treatment of addiction: methadone. J. Addict. Dis., 2010, 29(2), 200-216.
3. Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev., 2011, 16(2), CD001333.
4. Kosten, T.; Owens, S.M. Immunotherapy for the treatment of drug abuse. Pharmacol. Ther., 2005, 108, 76-85.
5. Orson, F.M.; Kinsey, B.M.; Singh, R.A.; Wu, Y.; Gardner, T.; Kosten, T.R. Substance abuse vaccines. Ann. NY Acad. Sci., 2008, 1141, 257-269.
6. Haney, M.; Kosten, T.R. Therapeutic vaccines for substance dependence. Expert Rev. Vaccines, 2004, 3, 11-18.
7. Volkow, N.D.; Wang, G.J.; Fowler, J.S.; Tomasi, D.; Telang, F. Quantification of Behavior Sackler Colloquium, Addiction, Beyond dopamine reward circuitry. Proc. Natl. Acad. Sci. USA, 2011, 15037-15042.
8. Nelson, R.A.; Boyd, S.J.; Ziegelstein, R.C.; Herning, R.; Cadet, J.L.; Henningfield, J.E.; Schuster, C.R.; Contoreggi, C.; Gorelick, D.A. Effect of rate of administration on subjective and physiological effects of intravenous cocaine in humans. Drug Alcohol Depend., 2006, 82(1), 19-24.
9. Cornish, J.W.; O'Brien, C.P. Crack cocaine abuse, an epidemic with many public health consequences. Annu. Rev. Public Health, 1996, 17, 259-273.
10. Walsh, S.L.; Stoops, W.W.; Moody, D.E.; Lin, S.N.; Bigelow, G.E. Repeated dosing with oral cocaine in humans, Assessment of direct effects, withdrawal, and pharmacokinetics. Exp. Clin. Psychopharmacol., 2009, 17, 205-216.
11. Smith, B.J.; Jones, H.E.; Griffiths, R.R.; Physiological, subjective and reinforcing effects of oral and intravenous cocaine in humans. Psychopharmacology (Berl.), 2001, 156, 435-444.
12. Rush CR, Baker RW, Wright K. Acute physiological and behavioral effects of oral cocaine in humans, a dose-response analysis. Drug Alcohol Depend., 1999, 55, 1-12.
13. Plotkin, S.A., Ed.; History of Vaccine Development; Springer, New York Dordrecht Heidelberg London, 2009.
14. Curd, J.; Smith, T.W.; Jaton, J.C.; Haber, E. The isolation of digoxin-specific antibody and its use in reversing the effects of digoxin. Proc. Natl. Acad. Sci. USA, 1971, 68(10), 2401-2406.
15. Berkowitz, B.; Spector, S. Evidence for active immunity to morphine in mice. Science, 1972, 178, 1290-1292.
16. Bonese, K.F.; Wainer, B.H.; Fitch, F.W.; Rothberg, R.M.; Schuster, C.R. Changes in heroin self-administration by a rhesus monkey after morphine immunization. Nature, 1974, 252(5485), 708-710.
17. Martell, B.A.; Mitchell, E.; Poling, J.; Gonsai, K.; Kosten, T.R. Vaccine pharmacotherapy for the treatment of cocaine dependence. Biol. Psych., 2005, 58, 158-164.
18. Martell, B.A.; Orson, F.M.; Poling, J.; Mitchell, E.; Rossen, R.D.; Gardner, T.; Kosten, T.R. Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients, a randomized, double blind, placebo-controlled efficacy trial. Arch. Gen. Psych., 2009, 66(10), 1116-1123.
19. Kosten, T.R.; Rosen, M.; Bond, J.; Settles, M., St.; Roberts, C.J.; Shields, J.; Jack, L.; Fox, B. Human therapeutic cocaine vaccine, safety and immunogenicity. Vaccine, 2002, 20, 1196-1204.
20. Haney, M.; Gunderson, E.W.; Jiang, H.; Collins, E.D.; Foltin, R.W. Cocaine-specific antibodies blunt the subjective effects of smoked cocaine in humans. Biol. Psychiatry, 2010, 67(1), 59-65.
21. Orson, F.M.; Kinsey, B.M.; Singh, R.A.; Wu, Y.; Kosten, T.R. Vaccines for cocaine abuse. Hum. Vaccin., 2009, 5(4), 194-199.
22. Dole, V.P.; Nyswander, M.E. Methadone maintenance treatment. A ten-year perspective. JAMA, 1976, 235(19), 2117-2119.
23. Kosten, T.R.; Kreek, M.J.; Ragunath, J.; Kleber, H.D. Cortisol levels during chronic naltrexone maintenance treatment in exopiate addicts. Biol. Psychiatry, 1986, 21(2), 217-220.
24. Deng, S.X.; de Prada, P.; Landry, D.W. Anticocaine catalytic antibodies. J. Immunol. Methods, 2002, 269(1-2), 299-310.
25. Lindroth, K.; Mastache, E.F.; Roos, I.; Fernández, A.G.; Fernández, C. Understanding thymus-independent antigen-induced reduction of thymus-dependent immune responses. Immunology, 2004, 112(3), 413-419.
26. Stewart, D.J.; Inaba, T.; Lucassen, M.; Kalow, W. Cocaine metabolism, cocaine and norcocaine hydrolysis by liver and serum esterases. Clin. Pharmacol. Ther., 1979, 25, 464-468.
27. Williams, R.H.; Maggiore, J.A.; Shah, S.M.; Erickson, T.B.; Negrusz, A. Cocaine and its major metabolites in plasma and urine samples from patients in an urban emergency medicine setting. J. Anal Toxicol., 2000, 24, 478-481.
28. de Wit, H. Priming effects with drugs and other reinforcers. Exp. Clin. Psychopharm., 1996, 4, 5-10.